ArticleMolecular therapy : the journal of the American Society of Gene Therapy2011
Replication-competent lentivirus analysis of clinical grade vector products.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Article
- Enhanced transcriptional insulation of lentiviral vectors using "sequence-upgraded polyA long terminal repeats" or "supA-LTRs".Molecular therapy. Advances · 2026Article
- FromImmune network · 2026Review
- Risks of replication-competent retro/lentivirus from associated vector systems: Is it time for a roadmap toward reduced testing?Molecular therapy. Methods & clinical development · 2025Review
- Lentiviral vector packaging and producer cell lines yield titers equivalent to the industry-standard four-plasmid process.Molecular therapy. Methods & clinical development · 2024Article
- Lentiviral Vectors for Ocular Gene Therapy.Pharmaceutics · 2022Review
- Review
- Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VIII: CAR-T cells: preclinical development - Safety and efficacy evaluation.Hematology, transfusion and cell therapy · 2021Article
- Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?Frontiers in pediatrics · 2021Review
- Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL PatientsTurkish journal of haematology : official journal of Turkish Society of Haematology · 2020Article
- Production of Therapeutic Enzymes by Lentivirus Transgenesis.Advances in experimental medicine and biology · 2019Review
- Detection of Replication Competent Lentivirus Using a qPCR Assay for VSV-G.Molecular therapy. Methods & clinical development · 2018Article
- Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Review
- Long-Term Safety Follow-Up of Subjects Previously Treated with Non-Replicating Retroviral Vector-Based Gene Therapies.Molecular diagnosis & therapy · 2016Article
- Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.Human gene therapy · 2016Article
- High-level production of replication-defective human immunodeficiency type 1 virus vector particles using helper-dependent adenovirus vectors.Molecular therapy. Methods & clinical development · 2015Article
- Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectors.Molecular therapy. Methods & clinical development · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Lentiviral vectors are now in clinical trials for a variety of inherited and acquired disorders. A challenge for moving any viral vector into the clinic is the ability to screen the vector product for the presence of replication-competent virus. Assay development for replication-competent lentivirus (RCL) is particularly challenging because recombination of vector packaging plasmids and cellular DNA leading to RCL has not been reported with the current viral vector systems. Therefore, the genomic structure of a RCL remains theoretical. In this report, we describe a highly sensitive RCL assay suitable for screening vector product and have screened large-scale vector supernatant, cells used in vector production, and cells transduced with clinical grade vector. We discuss the limitations and challenges of the current assay, and suggest modifications that may improve the suitability of this assay for screening US Food and Drug Administration (US FDA)-licensed products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.